Eli Lilly and Co. spent nearly $2 million in the first half of 2007 to lobby the federal government, the Associated Press reported today.
The Indianapolis-based drug maker lobbied on issues related to patent reform, intellectual property, counterfeiting, prescription drug user fees, health care reform and Medicare, according to the form posted online Aug. 13 by the Senate’s public records office.
Besides Congress, Lilly also lobbied the Food and Drug Administration, the departments of Commerce, Health and Human Services and State, and other federal agencies.
Please enable JavaScript to view this content.